​

Shattuck Labs Stock (NASDAQ:STTK)

ForecastRevenueOwnershipFinancialsChart
Shattuck Labs by TradingView

Previous Close

$2.14

52W Range

$0.69 - $3.95

50D Avg

$1.07

200D Avg

$1.09

Market Cap

$92.93M

Avg Vol (3M)

$2.34M

Beta

1.65

Div Yield

-

STTK Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

44

IPO Date

Oct 09, 2020

Website

STTK Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24
License$3.40M

Fiscal year ends in Dec 24 | Currency in USD

STTK Financial Summary

Dec 24Dec 23Dec 22
Revenue$5.72M$1.66M$652.00K
Operating Income$-80.57M$-91.96M$-103.33M
Net Income$-75.41M$-87.30M$-100.56M
EBITDA$-80.57M$-87.61M$-100.26M
Basic EPS$-1.49$-2.05$-2.37
Diluted EPS$-1.49$-2.05$-2.37

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 23Nov 10, 23 | 8:00 AM
Q4 22Feb 26, 23 | 4:45 PM
Q3 22Nov 12, 22 | 4:30 PM

Peer Comparison

TickerCompany
FHTXFoghorn Therapeutics Inc.
CCCCC4 Therapeutics, Inc.
SPRBSpruce Biosciences, Inc.
RZLTRezolute, Inc.
PRLDPrelude Therapeutics Incorporated